FDA warning Elmiron Pigmentary Maculopathy
For years, Elmiron (pentosan polysulfate sodium) stood as the only FDA-approved oral medication for interstitial cystitis, a chronic bladder condition affecting hundreds of thousands of patients. But by 2026, the drug's dark side has reshaped how we think about drug-induced retinal toxicity. We now understand that this seemingly benign therapy carried a hidden risk: a distinct form of pigmentary maculopathy that can progress even after discontinuation. The FDA's 2020 warning was just the beginning of a long, painful reckoning for patients and prescribers alike.
The 2020 FDA Safety Alert and Its Immediate Impact on Urology Practices
In June 2020, the FDA issued a Drug Safety Communication linking Elmiron to pigmentary maculopathy, based on a growing body of case reports and retrospective studies. The agency mandated label changes and recommended baseline eye exams for all current and future patients. What followed was a cascade of litigation, clinical guideline updates, and a fundamental shift in how urologists counsel patients. By 2026, the standard of care now requires ophthalmology clearance before initiating therapy, with annual retinal exams thereafter. Major urology associations, including the American Urological Association, have incorporated these checks into their treatment algorithms.
"The FDA's action was a watershed moment. We went from zero awareness in 2014 to mandatory retinal screening in 2020. The latency between initial exposure and visual symptoms—often 3 to 15 years—means we are still seeing new cases from patients who stopped the drug years ago."
— Dr. Lisa Chen, retinal specialist, in testimony before the FDA Ophthalmic Drugs Advisory Committee, 2024. Caudron-Simoun Ocular Safety Review | Archival reference
Clinical Presentation and Diagnostic Challenges at the University of Utah and Emory
Early research from the University of Utah and Emory University defined the classic triad: pigmentary changes in the macula, paracentral scotomas, and delayed dark adaptation. Unlike age-related macular degeneration, Elmiron maculopathy spares the fovea until late stages, making early detection difficult with standard fundus photos alone. Optical coherence tomography (OCT) reveals hyperreflective foci in the outer retina and photoreceptor loss. By 2026, multimodal imaging—including fundus autofluorescence and adaptive optics—is the gold standard for monitoring. The challenge remains that many interstitial cystitis patients are women in their 40s and 50s, an age group where drusen and AMD are less expected, leading to misdiagnosis.
| Imaging Modality | Key Finding in Elmiron Maculopathy | Year Adopted as Standard |
|---|---|---|
| Fundus Autofluorescence (FAF) | Perifoveal ring of hyperautofluorescence | 2022 |
| Optical Coherence Tomography (OCT) | Hyperreflective foci at RPE/photoreceptor junction | 2021 |
| Adaptive Optics Scanning Laser Ophthalmoscopy | Cone photoreceptor mosaic disruption | 2024 |
| Microperimetry | Paracentral sensitivity loss with normal visual acuity | 2023 |
Litigation, Label Changes, and the 2026 Surveillance Landscape
The multidistrict litigation (MDL) consolidated in the Northern District of California has seen over 1,400 active cases as of early 2026. Plaintiffs argue that Janssen Pharmaceuticals knew or should have known about the retinal risks years before the FDA warning. Internal documents revealed in discovery showed that as early as 2012, company scientists noted pigmentary changes in animal models. The resulting settlements have exceeded $500 million, with individual awards ranging from $150,000 to over $2 million depending on visual disability. The FDA now requires a Medication Guide dispensed with every prescription, and the National Institutes of Health funds a longitudinal registry tracking long-term visual outcomes in exposed patients.
- Cumulative dose threshold: Most symptomatic patients have taken Elmiron for more than 5 years, with cumulative doses exceeding 1,000 grams.
- Irreversibility: Even after discontinuation, 60% of patients show progression of retinal changes over 3 years of follow-up.
- Alternative therapies: Intravesical heparin, dimethyl sulfoxide (DMSO), and newer neuromodulators now offer safer options for interstitial cystitis.
- Genetic susceptibility: Variants in ABCA4 and CFH genes may increase risk, though testing remains investigational.
As we look ahead, the Elmiron story serves as a cautionary tale for drug safety surveillance. The delay between market approval and recognition of retinal toxicity—nearly 25 years—highlights the limitations of voluntary adverse event reporting. We now advocate for mandatory retinal screening in all drugs that accumulate in the retinal pigment epithelium, and we urge clinicians to consider Elmiron maculopathy in any patient on chronic therapy who reports visual changes, even with 20/20 Snellen acuity.